The proinflammatory cytokines tumor necrosis factor (TNF) a and interleukin (IL) 1b have been strongly implicated in the pathogenesis of neuropathic pain, but the intracellular signaling of these cytokines in glial cells is not fully understood. TNF receptor-associated factor 6 (TRAF6) plays a key role in signal transduction in the TNF receptor superfamily and the IL-1 receptor superfamily. In this study, we investigated the role of TRAF6 in neuropathic pain in mice after spinal nerve ligation (SNL). SNL induced persistent TRAF6 upregulation in the spinal cord. Interestingly, TRAF6 was mainly colocalized with the astrocytic marker glial fibrillary acidic protein on SNL day 10 and partially expressed in microglia on SNL day 3. In cultured astrocytes, TRAF6 was upregulated after exposure to TNF-a or IL-1b. TNF-a or IL-1b also increased CCL2 expression, which was suppressed by both siRNA and shRNA targeting TRAF6. TRAF6 siRNA treatment also inhibited the phosphorylation of c-Jun N-terminal kinase (JNK) in astrocytes induced by TNF-a or IL-1b. JNK inhibitor D-NKI-1 dose-dependently decreased IL-1b-induced CCL2 expression. Moreover, spinal injection of TRAF6 siRNA decreased intrathecal TNF-a-or IL-1b-induced allodynia and hyperalgesia. Spinal TRAF6 inhibition via TRAF6 siRNA, shRNA lentivirus, or antisense oligodeoxynucleotides partially reversed SNL-induced neuropathic pain and spinal CCL2 expression. Finally, intrathecal injection of TNF-a-activated astrocytes induced mechanical allodynia, which was attenuated by pretreatment of astrocytes with TRAF6 siRNA. Taken together, the results suggest that TRAF6, upregulated in spinal cord astrocytes in the late phase after nerve injury, maintains neuropathic pain by integrating TNF-a and IL-1b signaling and activating the JNK/CCL2 pathway in astrocytes.
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Introduction
The tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are a family of genetically conserved adapter proteins that consists of 6 members (TRAF1-6) in mammals [2] . Among all the family members, TRAF6 is unique in that it not only mediates signaling from the TNF receptor (TNFR) superfamily, but also participates in signal transduction in the interleukin (IL)-1 receptor/ Toll-like receptor (IL-1R/TLR) superfamily [3, 27] . By linking the activation of these receptors to downstream signaling events, TRAF6 exerts critical functions in a wide range of physiological and pathological processes, such as adaptive and innate immunity, inflammation, and tissue homeostasis [50] .
Neuropathic pain is caused by lesion or dysfunction of the nervous system. It is one of the most intractable human complaints and largely resistant to the current treatments [8] . It has become clear that activation of spinal cord glial cells such as microglia and astrocytes play an important role in the establishment and maintenance of neuropathic pain [19, 35, 44] . After tissue or nerve damage, the proinflammatory cytokines (eg, TNF-a and IL-1b) and chemokines (eg, CCL2) are upregulated in spinal cord glial cells [19, 41] . Targeting glia-expressing signaling molecules such as TNFa, IL-1b, and CCL2 has been shown to alleviate neuropathic pain [12, 33, 48] . Given the fact that TRAF6 is a key signaling integrator of TNF-a and IL-1b, it is conceivable to postulate that TRAF6 would play a critical role in the pathogenesis of neuropathic pain. 
